Imiprothrin
Imiprothrin is an inducer that induces CYP1A2 and metallothionein 1a, with significant genotoxicity and cytotoxicity. In rat hepatocytes, Imiprothrin initiates detoxification responses by triggering the overexpression of these two genes. Imiprothrin induces chromosomal aberrations and micronucleus formation in rat bone marrow cells, and causes DNA damage in hepatocytes. Imiprothrin triggers oxidative stress in rats, leading to lipid peroxidation, excessive reactive oxygen species production and redox imbalance, which in turn impairs liver and kidney functions and causes tissue damage. Imiprothrin inhibits weight gain in mice, and even causes high mortality in female mice at high doses. However, it shows no carcinogenicity in rat experiments; among relevant indicators, aspartate aminotransferase and total protein are identified as sensitive toxicity biomarkers.
For research use only. We do not sell to patients.
- CAS No.: 72963-72-5
- Formula: C17H22N2O4
- Molecular Weight:318.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
CYP1A2 |
In Vitro
Imiprothrin (75-100 μg/mL) induces chromosomal aberrations in Chinese hamster lung cells[1].
Imiprothrin does not induce mutagenicity in Salmonella or E. coli cells in Ames assays conducted with or without metabolic activation[2].
Imiprothrin does not induce gene mutations in Chinese hamster cells in an in vitro gene mutation assay[2].
Imiprothrin induces chromosomal aberrations in Chinese hamster lung cells in vitro in the presence of S9 metabolic activation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Imiprothrin (100-7000 ppm; p.o.; ad libitum; 78 consecutive weeks) shows marginal, non-robust increases in mouse lung tumor incidence only at the 7000 ppm dose, which exceeds the maximum tolerated dose (MTD) and produces significant systemic toxicity, while no significant carcinogenic effects are observed at doses at or below the MTD[2].
Imiprothrin (50-5000 ppm; p.o.; ad libitum; 104 consecutive weeks) shows no evidence of carcinogenic activity in rats up to the maximum tested dose of 5000 ppm, with only mild, non-carcinogenic systemic toxicity observed at the highest dose[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Crj:CD(SD) rat with Carcinogenicity (male/female, 6 weeks old, initial body weight 130-239 g)[2]
-
Dosage:50 ppm (average intake 1.8 mg/kg/day males, 2.2 mg/kg/day females); 250 ppm (average intake 8.7 mg/kg/day males, 10.7 mg/kg/day females); 2500 ppm (average intake 89.6 mg/kg/day males, 108.5 mg/kg/day females); 5000 ppm (average intake 180.2 mg/kg/day males, 218.5 mg/kg/day females)
-
Administration:p.o.; ad libitum; 104 consecutive weeks
-
Result:Showed no significant changes in tumor incidence, survival, body weight, hematology, organ weights, or histopathology relative to control at 50 ppm and 250 ppm.
Caused acinar cell hypertrophy of the submandibular gland in both sexes; showed no significant increases in tumor incidence in any tissue at 2500 ppm.
Reduced male final body weight by 4% and female final body weight by 7% relative to control; caused decreased mean corpuscular volume in males, increased lymphocyte and basophil counts in females; increased relative weight of salivary glands (both sexes), heart, prostate, and thyroid (males); caused acinar cell hypertrophy of the submandibular gland in both sexes; showed no significant increases in tumor incidence in any tissue at 5000 ppm.
Detected no treatment-related increases in benign, malignant, or total tumor numbers, or tumor-bearing animal counts across all doses.
Chemical Information
-
CAS No. 72963-72-5
-
Molecular Weight 318.37
-
Formula C17H22N2O4
-
SMILES
O=C(OCN1C(=O)N(CC#C)CC1=O)C2C(C=C(C)C)C2(C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Carcinogenicity Bioassay
A carcinogenicity bioassay detects whether long-term exposure to a test substance increases benign or malignant tumor incidence, changes tumor spectrum, or shortens tumor latency in experimental animals; the classical rodent design exposes rats and/or mice to multiple dose levels for most of their lifespan, followed by complete necropsy and histopathologic diagnosis of neoplastic and non-neoplastic lesions. The readout is tumor incidence by organ, sex, species, dose group, and survival status; interpretation requires concurrent controls, dose-response assessment, survival-adjusted tumor statistics, and pathology review because mortality, spontaneous tumor background, and body-weight effects can influence apparent tumor rates.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Protein Extraction
Protein extraction uses physical, chemical or biological methods, such as ultrasonic disruption, salting out, cell lysis, electrophoresis, etc., to destroy the cell membrane structure and to separate the proteins from different components according to their characteristics.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
[1]. Mohafrash SMM, et al. Detoxification gene expression, genotoxicity, and hepatorenal damage induced by subacute exposure to the new pyrethroid, imiprothrin, in rats. Environ Sci Pollut Res Int. Published online February 27, 2021. [Content Brief]
[2]. Yamada T, et al. Toxicological evaluation of carcinogenicity of the pyrethroid imiprothrin in rats and mice. Regul Toxicol Pharmacol. 2019;105:1-14. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)